Comparative clinical-economic study of the feasibility of risperidone used in the form of oral solution and tablets
K.S. ALTYNBEKOV
Republican Scientific-practical Center for Mental Health of the Ministry of Health of Kazakhstan, 88 Amangeldy Str., Almaty, Kazakhstan, 050022
Altynbekov K.S. ― Cand. Med. Sc., psychiatrist of Organizational-Methodological Consultancy Department, tel. (701) 775-55-13, e-mail: kuanysh_altyn@mail.ru
The article presents the results of the comparative complex (pharmacokinetic, clinico-dynamic and pharmakoeconomic) analysis of risperidone in the original (oral solution) and generic (tablets) forms. The research results have not confirmed the pharmacokinetic and therapeutic equivalence of the original and generic risperidone.
Key words: risperidone, pharmacokinetic and therapeutic equivalence, pharmakoeconomic analysis.
REFERENCES
- Janoutová J., Janácková P., Serý O., et al. Epidemiology and risk factors of schizophrenia. Neuro Endocrinol Lett, 2016, no. 37 (1), pp. 1-8.
- Lyubov E.B. Socio-economic burden of schizophrenia. Sotsial’naya i klinicheskaya psikhiatriya, 2012, vol. 22, no. 2, pp. 100-108 (in Russ.).
- Gurovich I.Ya., Lyubov E.B. Farmakoepidemiologiya i farmakoekonomika v psikhiatrii [Pharmacoepidemiology and pharmacoeconomics in psychiatry]. Moscow: Medpraktika, 2003. P. 264.
- Lyubov E.B. Pharmacoeconomic research in psychiatry. Sotsial’naya i klinicheskaya psikhiatriya, 1999, vol. 9, no. 1, pp. 89-96 (in Russ.).
- Kucukalio A., Srkalovio A.P., Oremus M., Rustempasio E. Observational postmarketing study on efficacy and safety of novel generic risperidonerisset(r) in patients with acute or chronic schizophrenic or other related psychosis. Psychiatr. Danub, 2014, vol. 16, pp. 79-87.
- Gurovich I.Ya., Lyubov E.B. Farmakoepidemiologiya i farmakoekonomika v psikhiatrii [Pharmacoepidemiology and pharmacoeconomics in psychiatry]. Moscow: Medpraktika, 2003. P. 264.
- Reshet’ko O.V., Nosova P.V., Baryl’nik Yu.B. Pharmacoepidemiology of psychotropic drugs used to treat paranoid schizophrenia in hospitals of various types. Klinicheskaya farmakologiya i terapiya, 2013, no. 3, pp. 71-75 (in Russ.).
- Vulis A.Ya., Sheyfer M.S., Nosenko N.F., Peshkov A.B. Experience of risperidone therapy of mental disorders in a psychiatric hospital. Sotsial’naya i klinicheskaya psikhiatriya, 2000, no. 3, pp. 64-67 (in Russ.).
- Heres S., Kissling W., Lloyd K. et al. Direct transition to long-acting risperidone ― analysis of long-term efficacy. J. Psychopharmacol, 2005, no. 19, suppl. 5, pp. 15-21.
- Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med, 2005, vol. 353, pp. 1209-1223.
- Gardner D.M., Baldessarini R.J., Waraich P. Modern antipsychotic drugs: a critical overview. J. Clin. Psychiatry, 2005, vol. 172, no. 13, pp. 1703-1711.